After three and a half years after the SARS-CoV-2 betacoronavirus began infecting people, 183 separate vaccines have entered clinical development.
Given this unprecedented response by vaccine developers, it could easily be assumed that COVID-19 vaccines have revealed all there is to know.
However, in The Lancet Respiratory Medicine, Gustavo Dayan and colleagues report the results of a phase 3 efficacy trial of a bivalent protein-based SARS-CoV-2 vaccine, offering new insights into vaccine-mediated protection against COVID-19.
Read More
